Steven Simonson
Chief Tech/Sci/R&D Officer chez WINDTREE THERAPEUTICS, INC.
Fortune : 6 176 $ au 31/03/2024
Profil
Steven G.
Simonson is currently the Chief Medical Officer & Senior Vice President at Windtree Therapeutics, Inc. He previously worked as the Executive Director-Molecule Development Group at Labcorp Drug Development, Inc. and as the Vice President-Clinical Development at Agennix, Inc. He also held the position of Vice President-Clinical Development at Agennix AG from 2011 to 2012.
Dr. Simonson obtained a doctorate degree from The Medical College of Wisconsin, Inc. and a graduate degree from Duke University School of Medicine.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 16/04/2024 | 17 446 ( 0,21% ) | 6 176 $ | 31/03/2024 |
Postes actifs de Steven Simonson
| Sociétés | Poste | Début |
|---|---|---|
| WINDTREE THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01/10/2014 |
Anciens postes connus de Steven Simonson
| Sociétés | Poste | Fin |
|---|---|---|
| AGENNIX AG | Chief Tech/Sci/R&D Officer | 18/04/2011 |
Agennix, Inc.
 Agennix, Inc. Pharmaceuticals: MajorHealth Technology Agennix, Inc. develops drugs for the treatment of cancer and wound healing. It develops liquid formulation of talactoferrin for cancer indications and a topical gel formulation for the treatment of diabetic foot ulcers. The company is headquartered in Houston, TX. | Corporate Officer/Principal | 01/11/2012 |
| COVANCE INC. | Corporate Officer/Principal | - |
Formation de Steven Simonson
| The Medical College of Wisconsin, Inc. | Doctorate Degree |
| Duke University School of Medicine | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| WINDTREE THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Labcorp Drug Development, Inc.
 Labcorp Drug Development, Inc. Pharmaceuticals: MajorHealth Technology Covance, Inc. operates as a contract research organization and drug development company. Its services include research, lead optimization, analysis services, safety assessment and drug safety testing, consulting and partnering, clinical development, informatics, clinical testing, commercialization, and manufacturing support. The company was founded on November 12, 1996 and is headquartered in Princeton, NJ. | Health Technology |
Agennix, Inc.
Agennix, Inc. Pharmaceuticals: MajorHealth Technology Agennix, Inc. develops drugs for the treatment of cancer and wound healing. It develops liquid formulation of talactoferrin for cancer indications and a topical gel formulation for the treatment of diabetic foot ulcers. The company is headquartered in Houston, TX. | Health Technology |
Agennix AG
 Agennix AG BiotechnologyHealth Technology Agennix AG was a pharmaceutical company, which engaged in the development of protein-based drugs for oncology, asthma and wound healing. Its clinical development programs included oral talactoferrin alfa and RGB-286638. The company was founded in 1993 and was headquartered in Heidelberg, Germany. | Health Technology |
